To address functional and smile dysfunction associated with post–facial paralysis synkinesis, the senior author (B.A.) has offered “modified selective neurectomy” of the lower division of the facial nerve as a long-term solution. This article examines technical considerations and outcomes of this procedure.
A retrospective review was conducted of patients who underwent modified selective neurectomy of buccal and cervical branches of the facial nerve performed by a single surgeon over a 4½-year period. House-Brackmann facial grading scores, electronic clinician-graded facial function scale, and onabotulinumtoxinA (botulinum toxin type A) dosages were examined before and after the procedure.
Sixty-three patients underwent modified selective neurectomy between June 20, 2013, and August 12, 2017. There were no serious complications. The revision rate was 17 percent. Temporary oral incompetence was reported in seven patients (11 percent) postoperatively. A statistically significant improvement was achieved in electronic clinician-graded facial function scale analysis of nasolabial fold depth at rest, oral commissure movement with smile, nasolabial fold orientation with smile, nasolabial depth with smile, depressor labii inferioris lower lip movement, midfacial synkinesis, mentalis synkinesis, platysmal synkinesis, static score, dynamic score, synkinesis score, periocular score, lower face and neck score, and midface and smile score. There was a significant decrease in botulinum toxin type A dosage and House-Brackmann score after surgery.
Modified selective neurectomy of the buccal and cervical divisions of the facial nerve is an effective long-term treatment for smile dysfunction in patients with post–facial paralysis synkinesis.
Los Angeles, Beverly Hills, and Santa Barbara, Calif.; and Madison, Wis.
From the Department of Head and Neck Surgery, David Geffen School of Medicine at the University of California, Los Angeles; the Center for Advanced Facial Plastic Surgery; the Santa Barbara Plastic Surgery Center; the Facial Nerve Clinic, University of Wisconsin Hospitals and Clinics; the Department of Neurotology, House Clinic; the Department of Otolaryngology, University of Southern California, and Beverly Hills Ophthalmic Plastic and Reconstructive Surgery; Division of Oculoplastic Surgery, Department of Ophthalmology, and Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology–Head and Neck Surgery, Keck School of Medicine, University of Southern California.
Received for publication January 10, 2018; accepted September 27, 2018.
Disclosure:Drs. Massry and Azizzadeh receive royalties from Elsevier and Springer. Dr. Azizzadeh was a co-investigator for the Checkpoint head and neck nerve stimulator/locator product validation study (2004). The other authors have no financial interests or conflicts of interest to disclose. No funding was received for this article.
Supplemental digital content is available for this article. Direct URL citations appear in the text; simply type the URL address into any Web browser to access this content. Clickable links to the material are provided in the HTML text of this article on the Journal’s website (www.PRSJournal.com).
Babak Azizzadeh, M.D., The Center for Advanced Facial Plastic Surgery, 9401 Wilshire Boulevard, Suite 650, Beverly Hills, Calif. 90212, email@example.com